The incidence and clinical predictors of amiodarone pulmonary toxicity were examined in 573 patients treated with amiodarone for recurrent ventricular (456 patients) or supraventricular (117 patients) tachyarrhythmias. Amiodarone pulmonary toxicity was diagnosed in 33 of the 573 patients (5.8%), based on symptoms and new chest radiographic abnormalities (32 of 33 patients) and supported by abnormal pulmonary biopsy (13 of 14 patients), low pulmonary diffusion capacity (DLCO) (nine of 13 patients), and/or abnormal gallium lung scan (11 of 16 patients). Toxicity occurred between 6 days and 60 months of treatment for a cumulative risk of 9.1%, with the highest incidence occurring during the first 12 months (18 of 33 patients).
been reported to occur in 1-17% of treated cases and to have a potentially fatal course.1'6-13 Risk The present study was undertaken to determine the incidence and clinical features associated with amiodarone-induced pulmonary toxicity in a large series of patients treated at a single medical center. Also examined were the relations of preexisting pulmonary abnormalities, drug doses, and plasma drug concentrations to the development of amiodarone pulmonary toxicity.
Methods Patients
The study population comprised 573 patients who were treated at the Indiana University Medical Center and initiated amiodarone therapy between April After the release of amiodarone for noninvestigational use in March 1986, some patients opted for continued follow-up with their own referral physician. These patients, their physicians, or both were contacted by phone to ascertain pertinent follow-up information.
Other Investigations
Additional testing was performed to establish or confirm the diagnosis of amiodarone pulmonary toxicity in most cases. Gallium-67 citrate, 2-5 mCi, was administered intravenously, and scintigraphic images were obtained 48 hours after injection of the radioisotope. Increased lung uptake was interpreted as consistent with an inflammatory process.'7 Light and electron microscopic examination of lung tissue obtained by bronchoscopic or open lung biopsy was conducted for the following pathologic changes6"13: 1) hyperplasia of type II pneumocytes, 2) alveolar septal thickening, 3) intra-alveolar accumulation of foamy macrophages and pneumocytes, and 4) fibrosis. Bronchoalveolar lavage, more recently described in patients with suspected amiodarone lung toXicity,18"19 was done inconsistently in the present study. In all cases, alternative etiologies such as congestive heart failure, infection, or malignancy were excluded by right heart catheterization, trials of diuretic therapy, sputum examination, or more detailed radiographic procedures. Amiodarone therapy was discontinued when the diagnosis of toxicity was made. Diagnostic Citeria Amiodarone-induced pulmonary toxicity was a clinical diagnosis that required two or more of the following criteria: 1) new onset of pulmonary symptoms such as dyspnea, cough, or pleuritic chest pain; 2) new chest radiographic abnormality such as an interstitial or alveolar infiltrate; 3) a decrease in the DLCO of 20% from the pretreatment value, or if none was available, a value less than 80% of predicted; 4) abnormal lung uptake with gallium-67 radioisotope; and Figure 1 is the inverse of the survival curve or the cumulative incidence of amiodarone-associated pulmonary toxicity.
Results

Incidence and Time Course for Toxicity
Of the 573 patients who received amiodarone, 33 developed pulmonary toxicity, resulting in an overall incidence of 5.8%. The cumulative incidence of amiodarone pulmonary toxicity was 9.1% at 121 months of therapy using survival analysis (Figure 1 ). The highest risk for the development of toxicity, corresponding to the steepest portion of the curve, occurred during the first 12 months of therapy. After 12 months, the cumulative incidence of toxicity continued to rise steadily, reaching 9 Before the institution of a specific pulmonary follow-up protocol (1977-80), 20 patients discontinued amiodarone therapy. None of these patients had symptoms or signs suggestive of pulmonary toxicity, and only one patient discontinued the drug for unknown reasons.
Three hundred forty-one of the 573 patients were followed at Indiana University. Ninety-three percent of these subjects had had chest radiographs within 6 months of the conclusion of the study. We have no data among the 232 patients followed outside of Indiana University regarding completeness of chest radiography follow-up, after they were no longer followed by us, beginning March 1986. Presenting Symptoms
The presenting symptoms of amiodarone-induced pulmonary toxicity were known in 28 patients. The majority (71%) had dyspnea as the initial symptom. Other symptoms were cough (25%), fever (21%), nausea (7%), weakness or fatigue (7%), weight loss (4%), and pleuritic chest pain (4%).
Diagnostic Tests
The diagnostic tests used to establish and confirm the diagnosis of amiodarone pulmonary toxicity are outlined in Table 2 (Figure 2) . 
Pretreatment and Follow-up Radiographs
Analysis of pretreatment chest radiographs revealed no significant difference between patients who did and did not develop pulmonary toxicity. During follow-up, new chest radiographic abnormalities developed in 98 of 571 patients (17%). These new abnormalities were attributed to amiodarone pulmonary toxicity in 32 patients, whereas the remainder were secondary to congestive heart failure (34 patients), atelectasis (seven patients), chronic obstructive pulmonary disease (six patients), malignancy (four patients), and infection (three patients).
Twelve remaining patients had chest radiographic abnormalities of unknown etiology that resolved spontaneously despite continuation of amiodarone.
Pretreatment Pulmonary Function Tests
Pretreatment pulmonary function tests of the groups with and without pulmonary toxicity were compared. There was no significant difference in measured lung volumes or spirometry between these two groups (Table 3 ). Figure 3 compares the pre- Plasma Drug Concentrations Plasma concentrations of amiodarone and its metabolite, desethylamiodarone, were measured during the maintenance period of amiodarone therapy ( Figure 5 ). There was no difference in mean plasma amiodarone concentration between the groups with and without toxicity (3.04+±0.38 versus 2.83±0.06 ,xg/ml, p=0.46). However, the mean plasma desethylamiodarone concentrations were significantly higher in the group with pulmonary toxicity compared with the group without toxicity (2.34±+0.18 versus 1.92±0.04 4g/ml,p=0.009). There was a mean of 3.2 (range, 1-9) determinations of plasma drug and metabolite concentrations done per patient in the group with amiodarone pulmonary toxicity and a mean of 3.9 (range, 1-12) in the group without.
Amiodarone Drug Dose Analysis
Amiodarone dose data were calculated by two methods. The initial analysis defined the loading period as the number of days amiodarone was administered before a decrease to a stable dose. There was no significant difference between the group with and the group without amiodarone pulmonary toxicity with respect to the actual length of the loading period (mean, 35±12; range, 6-56 days versus mean, 36+16; range, 3-83 days, p =0.47) and the mean daily loading dose (838±40 versus 848+11 mg, p=0.79). During the maintenance period, however, the patients who developed toxicity received a significantly higher mean daily dose of amiodarone when compared with the group without toxicity (515+25 versus 409±6 mg,p<0.001).
The second analysis standardized the loading phase of amiodarone administration to be the first 30 days of drug treatment. During the loading period, there was no significant difference between the group with and the group without development of amiodarone pulmonary toxicity in the mean daily amiodarone dose (816+35 versus 832±10 mg, p=0.70). During the There were 197 total deaths in this patient population during the follow-up period, of which three were attributed to pulmonary toxicity as outlined above. One hundred forty-nine were due to a cardiac etiology, and 24 were noncardiovascular in origin. Twenty-one patients had unknown causes of death although symptoms suggesting pulmonary toxicity were not reported antemortem. Discussion In this large series of patients treated with amiodarone, 33 of 573 patients presented with overt clinical evidence of pulmonary toxicity. These patients usually were symptomatic, had new radiographic abnormalities, and had additional diagnostic studies to help confirm the diagnosis. The diagnosis was made by considering a constellation of clinical and laboratory findings, as no single test is pathognomonic for the disorder.
Incidence and Diagnosis of Toxicity
The reported incidence of amiodarone pulmonary toxicity in the literature depends on the diagnostic criteria used. Our incidence of 5.8% is similar to that previously reported6,8'13 and was based on the appearance of new symptomatology, most frequently dyspnea and cough, and confirmed with additional diagnostic testing, including radiographic and nuclear imaging, pulmonary function testing, and histologic examination. Pulmonary toxicity from amiodarone shares features with other drug-induced pneumonitis,1920 including the presence of activated inflammatory cells in the lungs that may be detected by the accumulation of gallium.17,2' Microscopic pathologic changes noted with lung biopsy likewise resembled other toxic drug effects in the lung and were not pathognomonic for amiodarone toxicity,6,13 but their presence was helpful in supporting the diagnosis. Smith et a110 and Haffajee et al1l' have both reported a low incidence (1%) of pulmonary toxicity although the diagnosis in these studies relied mostly on radiographic abnormalities without histologic support. This difference in diagnostic criteria and also relatively short follow-up (mean, 24 and 9 months, respectively) may be responsible in part for the low incidence of amiodarone pulmonary toxicity in these studies. A higher incidence (17%) of toxicity was reported by Magro et al,9 who used similar clinical diagnostic criteria to those used in the present study but emphasized symptoms and radiographic abnormalities without the aid of DLCO abnormalities. Differences in the patient populations studied and criteria used to make the diagnosis of amiodarone pulmonary toxicity may account for the observed discrepancies between our findings and those of Magro et al.9 Bronchoalveolar lavage, although not applied systematically in the present study, has been used to describe the cytologic changes that occur during amiodarone therapy, but its role in druginduced toxicity remains to be defined.
Demographic Factors Predisposing to Toxicity
When demographic parameters were analyzed, a higher occurrence of pneumonitis was found in the older patients. There were no cases of amiodarone pulmonary toxicity in those patients who started therapy at an age less than 40 years. This latter finding most likely explains the significant age difference found between our two groups with and without toxicity. Other clinical characteristics such as gender, underlying heart disease, and presenting arrhythmia were not identified as risk factors for development of toxicity. The highest risk for developing toxicity occurred during the first 12 months of treatment, and no new cases were diagnosed after 60 months of therapy. This peak in incidence early in treatment has also been observed by others. 9 Radiographic Abnornalities Pretreatment chest radiographic abnormalities did not identify a subset of patients at risk for developing pulmonary toxicity. New radiographic abnormalities were observed in 98 patients, but on further investigation, 67% of these were attributable to etiologies other than amiodarone toxicity. We currently recommend surveillance chest radiographs at 3-6-month intervals during maintenance amiodarone therapy, especially during the first 12 months when the risk appears to be highest. The use of routine chest radiographs during maintenance therapy complements the occurrence of new symptomatology, as the latter can be subtle and nonspecific, especially in patients with coexisting congestive heart failure or chronic obstructive lung disease.
A weakness of this analysis is our uncertainty regarding the extent to which chest radiography follow-up was obtained in patients not followed directly by us after March 1986. Though we believe that chest radiographic films were obtained at least every 6 months in most of those 232 patients, if they were not, then some cases of pulmonary toxicity could have been missed.
Pulmonary Function Testing Including Diffusion Capacity
Pretreatment spirometric or lung volume measurements were not helpful in identifying a high-risk group for developing pulmonary toxicity. An abnormally low pretreatment percent of predicted DLCO (i.e., less than 80%) did allow identification of patients who were at increased risk for developing toxicity. The wide range of DLCO values in both groups, with and without toxicity, did not allow for a specific discriminating pretreatment value that was predictive for the subsequent development of toxicity. When the data were analyzed using less than 80% of the predicted DLCO as the criterion for pretreatment abnormality, the sensitivity and specificity were only 65% and 68%, respectively, and the positive predictive value 11%. The negative predictive value of a normal pretreatment percent of predicted DLCO was 97%, however, and identified a group of patients at low risk for developing pulmonary toxicity. With the onset of pulmonary toxicity, a restrictive physiologic pattern was seen with a decrease in FVC and TLC and an increase in the FEV1IFVC ratio. The development of toxicity may be related to amiodarone dose, as there was a higher average daily dose administered to those patients who subsequently developed toxicity during the maintenance therapy. This relation of dose to the development of toxicity has been found by others.69 Our change to higher initial loading doses (1,600 mg/day) was not associated with an increased risk of toxicity. A dosedependent effect of the drug on cytotoxicity has been demonstrated in vitro.23 Total cumulative dose was originally calculated in the first 498 patients of this series to correlate this variable with the development of pulmonary toxicity. The group of patients developing toxicity had lower cumulative doses administered because these patients correspondingly had a shorter duration of therapy because of their censoring from the study at the time of diagnosis of pulmonary toxicity. Therefore, our approach of analyzing average daily doses both in the loading and maintenance phase of amiodarone therapy was used to circumvent this problem. Although no cases of amiodarone-induced pulmonary toxicity occurred in those patients who received less than 305 mg/day during maintenance therapy in our patient population, toxicity has been reported during low-dose maintenance therapy. 24 In the present study, because there was no relation between age and drug dose, amiodarone dose was not responsible for the decreased risk seen in the younger patients.
Plasma Drug Concentrations and Relation to Toxicity
Measurements of plasma drug concentrations during therapy revealed significantly higher mean desethylamiodarone but not amiodarone concentrations in the group that developed toxicity. A relation between higher amiodarone concentrations and development of drug side effects such as hepatic dysfunction and neuromuscular and ocular effects has been shown previously.2526 but pulmonary toxicity was also shown to occur at lower concentrations.26 It is presently unclear whether desethylamiodarone plays a role in the development of pulmonary toxicity, other than that plasma concentrations tend to correlate with amiodarone doses administered during maintenance therapy.14
Clinical Implications
Amiodarone-induced pulmonary toxicity remains a significant complication of therapy with this antiarrhythmic agent and can result in death. Risk may be minimized by administering the lowest effective daily dose of amiodarone during maintenance therapy.
The highest risk appears to occur in patients with abnormally low pretreatment pulmonary DLCO values, and this test may identify a higher risk patient for whom closer surveillance may be warranted. A high index of suspicion is often necessary in establishing the diagnosis of pulmonary toxicity, and most cases are reversible if detected early.
